SBIR/STTR Research Award
HLS-Highly-Sensitive, One-minute, Portable Diagnostic for Malaria Elimination
Award amount
$1,486,894Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- HEMEX HEALTH INC
- Proposal award date
- 2017-03-02
- Contract end date
- 2020-02-29
- UEI
- LSJ7WFKBJWW4
- Solicitation number
- PAR14-088
- Topic code
- NIAID
Research abstract
Project SummaryWhile the mosquito borne illness malariais entirely preventable and treatablecountries are
currently plagued by malaria transmission and half the world s population is at risk of malariaA great deal of
progress has been made against malaria as a result of the massive rollout of resources and technology
focused on malaria controlThirty five of theaffected countriesincluding China and Indiaare now focusing
on reaching malaria elimination byTo be successfully eliminate malaria these countries need to reach out and screen populations and
treat malaria in remote areasin communitiesand along bordersTodayeliminating malaria is hindered
because of the lack of a portable diagnostic screening tool that s capable of quickly detecting all types of
malariaeven at very low levels of infectionStudies have demonstrated that interrupting transmission requires
a focus on identification of all parasite carriersboth symptomatic and asymptomaticCurrent field based
diagnosticslight microscopy and RDTsare not sensitive enough for this task and molecular diagnosticsLAMP and PCRlack the affordabilityportabilityand high throughputThe goal of this project is to develop
and test an affordableportableone minutehighly sensitive malaria diagnostic device that accelerates efforts
to eliminate malariaA multidisciplinary team developed magneto optical detectionMODwhich finds malaria using the
biomarker hemozoinUsing hemozoinit is able to accurately detect all five species of malaria including those
with HRPdeletion and is sensitive even at very low concentrations of parasitesMOD is ideal for diagnostic
screening to aid elimination effortsIt is a ruggedportable device that can be easily used by entry level
healthcare workers anywhereIn one minute it provides accurate results on all species atX the sensitivity of
microscopy and it is highly affordable at $testIn this Phase II project the team will advance the product towards commercialization by finalizing the
product design with end user inputconducting bench testing to characterize performanceand performing
validation testing in multiple field settings including PeruKenya and IndiaThe overall objective is to support
developing country teamsin their move towards malaria eliminationby producing the tool they need to quickly
identify and treat malaria everywhere
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- RHODA: Rapid Hemoglobin-Oxygen Dissociation Assay
- Using an Inclined Plane System to Triage TBI Patients
- Affordable, quantitative, point-of-care microchip-electrophoresis for screening and treatment monitoring of sickle cell disease, thalassemias, and anemias
- Portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C testing
- Using Multi-Spectral Imaging with Microchip Electrophoresis to Accurately Screen Newborns for Sickle Cell Disease
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients